Pediatric Neurology News

Lysogene has announced topline results from its phase 2/3 study evaluating LYS-SAF302, an investigational gene therapy for the treatment of mucopolysaccharidosis type IIIA, or Sanfilippo syndrome.

SARS-CoV-2-related neurologic effects endured among children and adolescents in the United States who were hospitalized in 2021 for COVID-19 or multisystem inflammatory syndrome, researchers reported in JAMA Neurology.

Published results showed use of a novel hip brace was effective for preventing progression of hip displacement and improving quality of life in patients with nonambulatory cerebral palsy.

Children who played video games were shown to exhibit better cognitive function compared with those who didn’t, researchers reported in JAMA Network Open.

CHICAGO — Nicole Rosendale, MD, assistant professor of neurology at the University of California, San Francisco, discusses highlights from her talk at ANA 2022 on equity in neurologic care for the LGBTQ+ community.

WASHINGTON — Some infants with in utero or early life exposure to SARS-CoV-2 had borderline to low developmental scores, a study found, and this was most common among babies born to mothers with symptomatic COVID-19.

Daily treatment with risdiplam over 24 months resulted in improved motor function and achievement of developmental motor milestones in infants with type 1 spinal muscular atrophy, according to a study published in The Lancet Neurology.

Biotech firm SynaptixBio has entered into a licensing agreement with the Children’s Hospital of Philadelphia, also known as CHOP, to develop a treatment for TUBB4a leukodystrophy, a rare and fatal neurodegenerative disorder.

Antidepressant use in pregnancy was not associated with neurodevelopmental disorders in offspring, according to a cohort study published in JAMA Internal Medicine.

ANAHEIM, Calif. — Findings presented here suggest that young athletes may be at greater risk for head injuries on synthetic turf vs. natural grass fields.